欢迎访问《现代生物医学进展》编辑部！

目的：观察百乐眠胶囊联合alpha-受体阻滞剂治疗良性前列腺增生症引起的夜尿症的疗效。方法：随机选取符合良性前列腺增生症诊断，采用琢- 受体阻滞剂单药治疗，夜尿仍大于等于2 次的患者20 例，在继续服用alpha- 受体阻滞剂治疗的基础上，加用百乐眠胶囊，每日2 次，每次4 粒。加用百乐眠胶囊前和用药1 个月后，分别采用国际前列腺症状评分表（International Prostate Symptom Score, IPSS)，生活质量指数（quality of life index, QoL），膀胱过度活动症评分表（Overactive Bladder Symptom Score, OABSS）进行评估。结果：加用百乐眠胶囊1 月后，IPSS 评分表中夜尿评分从2.88 降至2.41（P=0.03），OABSS 评分表总分从6.31 降至5.38（P=0.03），夜尿评分从2.63 降至2.13（P=0.01），QoL评分无显著变化。结论：百乐眠胶囊联合alpha- 受体阻滞剂治疗良性前列腺增生症引起的夜尿症有较好的疗效。

英文摘要:

Objective:To evaluate the clinical effect of bailemian capsule combined with an alpha-blocker in the treatment of nocturia in men with benign prostatic hyperplasia.Methods:Subjects were 20 patients who had LUTS suggestive of benign prostate hyperplasia, received alpha-blockers ( tamsulosin or doxazosin mesylate ), and continued to have two or more episodes of nocturia per night. Bailemian capsule at 4 tablets twice daily for one month was added to the alpha-blocker. A self-administered questionnaire including the International Prostate SymptomScore (IPSS), quality of life (QoL) index, and Overactive Bladder Symptom Score (OABSS) were assessed before and one month after starting bailemian capsule.Results:The mean score on IPSS question 7 (nocturia) decreased significantly from 2.88 before starting bailemian capsule to 2.41 one month after starting the medication (P=0.03). The mean total OABSS decreased significantly from 6.31 to 5.38 (P=0.03), and the mean for OABSS question 2 (nighttime frequency of nocturia) also significantly decreased from2.63 to 2.13 (P=0.01). The mean QoL index did not change significantly.Conclusion:Bailemian capsule in combination with an alpha -blocker can decrease the nocturia in men with BPH.

查看全文查看/发表评论下载PDF阅读器

关闭